Table 1 Characteristics of patients with association of AHA and plasma cell neoplasms – a systematic review
From: Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature
Patient no. | Author, year [reference] | Sex | Age (years) | Diagnosed first | Bleeding | FVIII:C (%) | FVIII inhibitor (BU/ml) | Hemostatic treatment | Treatment AHA inhibitor eradication | AHA outcome | Paraprotein | Treatment PCN | PCN outcome | Alive/died |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Glueck et al., 1965 [5] | M | 70 | PCN | MC, RT | NA | NA | NA | C | NA | NA | NA | NA | NA |
2 | Loftus et al., 1994 [6] | F | 58 | PCN | MC, A | 8 | 36 | FVIII, pFVIII | S, C | Bleeding continued | Lambda light chain | M | NA | Died of intra-abdominal bleeding |
3 | Stricker et al., 1994a [7] | M | 52 | PCN | I | 2 | 17.8 | FVIII, plasma | S, PEX | Normal APTT and FVIII:C | Kappa light chain | IFN-α, ASCT | CR | Died of sudden cardiac death |
4 | Sallah et al., 2000 [8] | F | 58 | AHA | MC | < 1 | 28 | pFVIII, APCC | S, PEX | Inhibitor persisted | NA | M | Died | Died of acute renal failure/hemorrhage |
5 | Holme et al., 2005 [9] | M | 58 | AHA | I | 6 | 20 | APCC | S, C | NA | NA | NA | PR | Alive |
6 | Sari et al. 2009 [10] | F | 43 | AHA | I | 6 | 10 | No treatment | No treatment | Normal coagulation | IgG kappa | VinOD, ASCT | CR | NA |
7 | Decaux et al. 2009 [11] | F | 44 | PCN | MC | 6 | 29 | rFVIIa | R | NA | IgA kappa | NA | NA | NA |
8 | Muzaffar et al. [12] | M | 65 | PCN | PE, HA | < 5 | 9.5 | APCC, plasma | IVIG, R | FVIII:C 22%, no FVIII inhibitor | Lambda light chain | VTD | CR | Alive |
9 | Saburi et al. 2015a [13] | F | 67 | PCN | NA | 2 | 4.9 | No treatment | S, C | Normal APTT, FVIII inhibitor 4.85 BU/ml | NA | VD, LCD | CR | NA |
10 | Ross et al. [14] | F | 64 | AHA | MC, HP | 17 | 5 | rFVIIa | S | Normal coagulation | IgM kappa | VTD | NA | NA |
11 | Innao et al. [15] | M | 67 | PCN | NA | 28 | NA | FVIII | No treatment | Normal coagulation | IgG kappa, kappa light chain | VMP, ASCT | CR | Alive |
12 | Brás, et al. [16] | M | 87 | PCN | MC, IM | 1.4 | 18.4 | APPC | S, C, B | Normal APTT, FVIII:C 36%, FVIII inhibitor 0.8 BU/ml | IgG kappa | MTP, VD | PR | NA |
13 | Napolitano et al. 2017 [17] | F | 59 | AHA | MC, HA, A | 12 | 70 | rFVIIa, APCC | S, R | Normal coagulation | IgG lambda | VMP | CR | Alive |
14 | Kawashima et al. 2018 [18] | M | 52 | PCN | IM | 17 | 1 | rFVIIa | No treatment | Normal coagulation | IgA kappa | VD, VCD, VTD, LD, ASCT, allo-HCT | CR | NA |
15 | Sourdeau et al. 2019 [19] | M | 78 | PCN | ST | < 1 | 19 | NA | NA | NA | NA | VCD | NA | NA |
16 | Our patient | M | 77 | AHA | IM | 2 | 102 | rFVIIab | S, C, IA | Normal APTT, normal FVIII | IgG kappa | VRD, RD | VGPR | Alive |